MedTrace Logo

the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma

NCT01717066 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 480

Last updated 2016-03-31

No results posted yet for this study

Summary

Using the subject with hepatocellular carcinoma in the conventional therapy to evaluate the efficacy and safety of ginsenoside Rg3 (20mg BID) and placebo in prevention and treatment of postoperative recurrence of liver cancer,respectively

Conditions

  • Stage I Hepatocellular Carcinoma
  • Stage II Hepatocellular Carcinoma

Interventions

DRUG

the ginsenoside Rg3

DRUG

Placebo

Sponsors & Collaborators

  • Huazhong University of Science and Technology

    collaborator OTHER

  • Shanghai Zhongshan Hospital

    collaborator OTHER

  • Sun Yat-sen University

    collaborator OTHER

  • First Affiliated Hospital of Harbin Medical University

    collaborator OTHER

  • First Affiliated Hospital of Fujian Medical University

    collaborator OTHER

  • ShenFeng

    lead OTHER

Principal Investigators

  • Feng Shen, MD,PhD · Eastern Hepatobiliary Surgery Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2014-12-31
Completion
2015-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01717066 on ClinicalTrials.gov